Literature DB >> 15698675

Outcome of a first episode of psychosis in adolescence: a 2-year follow-up.

Alissa Pencer1, Jean Addington, Donald Addington.   

Abstract

Symptomatic and functional outcome and cognitive functioning were examined in adolescents experiencing their first episode of psychosis. The adolescents (n=69) were assessed and compared with adults (n=69), all presenting for treatment for the first time to a specialized Early Psychosis Program. Assessments were conducted at the initial presentation, and at 1- and 2-year follow-ups. Assessments included positive and negative symptoms, depression, number of relapses, substance use, cognitive functioning, age-appropriate productivity (employment or being in school) and quality of life. Adolescents showed both symptomatic and functional improvement over 2 years of optimal treatment. Positive and negative symptoms predicted outcome at 2 years. Compared with adults, the adolescents had similar clinical and functional outcomes but used more cannabis and had an increased number of relapses. These adolescents are doing relatively well following their first episode and reinforce the need to address cannabis use as an integral part of a comprehensive treatment program.

Entities:  

Mesh:

Year:  2005        PMID: 15698675     DOI: 10.1016/j.psychres.2004.10.004

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  19 in total

1.  A comparison of adolescent- and adult-onset first-episode, non-affective psychosis: 2-year follow-up.

Authors:  Johannes Langeveld; Inge Joa; Svein Friis; Wenche ten Velden Hegelstad; Ingrid Melle; Jan O Johannessen; Stein Opjordsmoen; Erik Simonsen; Per Vaglum; Bjørn Auestad; Thomas McGlashan; Tor K Larsen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-23       Impact factor: 5.270

2.  Early-onset schizophrenia: a 15-year follow-up.

Authors:  Bernd Röpcke; Christian Eggers
Journal:  Eur Child Adolesc Psychiatry       Date:  2005-09       Impact factor: 4.785

Review 3.  Clinical usefulness of second-generation antipsychotics in treating children and adolescents diagnosed with bipolar or schizophrenic disorders.

Authors:  Salvatore Gentile
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

4.  Relationship between patterns of cannabis use and functional and symptomatic trajectories in first-episode psychosis.

Authors:  Abigail C Wright; Julia Browne; Corinne Cather; Piper Meyer-Kalos; Kim T Mueser
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-07-28       Impact factor: 5.760

5.  Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis.

Authors:  Joseph Ventura; Gerhard S Hellemann; April D Thames; Vanessa Koellner; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2009-07-22       Impact factor: 4.939

Review 6.  The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia?

Authors:  Lynn E DeLisi
Journal:  Curr Opin Psychiatry       Date:  2008-03       Impact factor: 4.741

7.  Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia.

Authors:  Stephen M Eggan; Takanori Hashimoto; David A Lewis
Journal:  Arch Gen Psychiatry       Date:  2008-07

8.  Models of substance use in adolescents with and without psychosis.

Authors:  Alissa Pencer; Jean Addington
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2008-11

9.  Psychosocial Interventions in Reducing Cannabis Use in Early Phase Psychosis: A Canadian Survey of Treatments Offered.

Authors:  Cristina Aydin; Philip G Tibbo; Zenovia Ursuliak
Journal:  Can J Psychiatry       Date:  2016-03-16       Impact factor: 4.356

10.  Screening for substance use disorders in first-episode psychosis: implications for readmission.

Authors:  Albert Batalla; Clemente Garcia-Rizo; Pere Castellví; Emili Fernandez-Egea; Murat Yücel; Eduard Parellada; Brian Kirkpatrick; Rocío Martin-Santos; Miguel Bernardo
Journal:  Schizophr Res       Date:  2013-03-19       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.